{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:boserolimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:runimotamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00654966: Phase 2 Interventional Completed Heart Failure
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03033524: Phase 2 Interventional Completed Recurrent Glioblastoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03123055: Phase 1/Phase 2 Interventional Terminated Locally Advanced or Metastatic Urothelial Cell Carcinoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04277598: Phase 1/Phase 2 Interventional Completed Diabetic Foot Ulcer (DFU)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04563923: Phase 2 Interventional Completed Bullous Pemphigoid
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03852719: Phase 3 Interventional Completed Chronic Hepatitis Delta
(2019)
Source URL:
Class:
PROTEIN
